About us

Deltamune, with a history dating back to 1977, is a Gauteng based South African company focusing on veterinary public health. Inactivated vaccines focusing on South African strains have been produced since 1980. The development of EU-USA tests for various poultry diseases commenced in 1985. At Deltamune we support our customers to achieve their production goals, backed by state of the art vaccines research and development, manufacture of biological products. Supported by an ISO 17025 (SANAS V.0007) accredited and Department of Agriculture, Forestry and Fisheries (DAFF) approved test laboratory.

Product Range and Capabilities

<table>
<thead>
<tr>
<th>Product Range</th>
<th>Capsules</th>
<th>Enteritis (A)</th>
<th>Leaky Gut Syndrome (A)</th>
<th>Coccidiosis</th>
<th>Influenza A Virus (AIV)</th>
<th>M. gallisepticum (MG)</th>
<th>Newcastle Disease (ND)</th>
<th>Ornithobacterium rhinotracheale (OR)</th>
<th>Pasteurella multocida (PM)</th>
<th>Pigeon Pox</th>
<th>Salmonella Enteritidis (SE)</th>
<th>Salmonella Gallinarum (SG)</th>
<th>Salmonella Infantis (SI)</th>
<th>Salmonella Muenchen (SM)</th>
<th>Salmonella Typhimurium (ST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVIVAC® AI</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AVIVAC® COR/EDS</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AVIVAC® CORYZA</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AVIVAC® ND</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AVIVAC® SE</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STRUVAC ND PLUS</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Autogenous vaccine solutions provided through veterinarians include: X X X X X X  

Contact us for solutions to your vaccination and laboratory needs
Email: info@deltamune.co.za Website: www.deltamune.co.za
Telephone: +27 (0)12 664 5730 Fax: +27 (0)12 664 5149
Registration holder: DELTAMUNE (PTY) LTD Reg 1994/005981/07
AVIVAC® SE is distributed by: Immunovet Services CC (Reg. No. 1998/025418/23)
Telephone: +27 (0)11 699-6240 Fax: +27 (0)11 462 0869
Website: www.immunovet.co.za Email: info@immunovet.co.za

AVIVAC® SE
A South African derived SE vaccine with proven benefits to humans and fowls
An oil-emulsion of inactivated Salmonella Enteritidis.
AVIVAC® SE is indicated for preventive immunisation of breeders and replacement pullets against Salmonella Enteritidis. Vaccination with AVIVAC® SE leads to a reduction of mortalities, less drop in egg production and a reduction in the isolation of Salmonella Enteritidis from organs of vaccinated fowls challenged with field strains of Salmonella Enteritidis.

AVIVAC® SE significantly reduces egg production losses in challenge groups*

AVIVAC® SE administration monitoring can be performed with ELISA test

What is Salmonella Enteritidis?

Salmonella Enteritidis is a contagious animal disease caused by a bacterium and characterised by septicemia in young poultry and a carrier state in older poultry. The control of Salmonella Enteritidis in commercial broilers or layers is most important as there are human health considerations (zoonosis), as well as economic considerations for the poultry producer. It is thus essential that control measures are meticulously followed to ensure that outbreaks and shedding of organisms do not occur in commercial broiler and layer flocks.

Effective immunisation with a suitable vaccine forms only part of a comprehensive Salmonella reduction plan which also entails strict biosecurity measures with an appropriate Salmonella monitoring plan in place.

Development of this vaccine was done according to GLP guidelines and animal studies performed following GCP guidelines. Manufacturing of the vaccine is conducted in a facility that adheres to European GMP guidelines, with virus propagated in specific pathogen free (SPF) embryonated chicken eggs. Sterility testing is performed in the Deltamune ISO 17025 accredited laboratory (SANAS V.0007: VAC-QCD-ME-019 method).

Advantages of using AVIVAC® SE

- Reduced mortalities
- Reduced drop in egg production
- Reduction in the isolation of SE from organs
- South African isolate used as base of the vaccine
- Oil adjuvated vaccine ensures high immune response and long duration of immunity
- World-class technical and laboratory support for the product provided by Deltamune

Recommended dosage

A dose of 0.5 mL should be injected intramuscularly into the breast muscle of replacement pullets or breeding fowls older than 6 weeks of age. A booster vaccination must be administered at least 4 weeks after the first one, but not within 4 weeks of onset of lay.

* Independent study conducted by the Poultry Reference Laboratory (University of Pretoria)